Valuation : Lexeo Therapeutics, Inc.

Market Cap 391M 336M 316M 288M 541M 37.16B 545M 3.74B 1.46B 18.84B 1.47B 1.43B 62.39B P/E 2026 *
-3.91x
P/E 2027 * -3.46x
Enterprise Value 213M 183M 172M 157M 295M 20.25B 297M 2.04B 793M 10.27B 799M 782M 34B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.36%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Lexeo Therapeutics, Inc.

1 day-2.06%
1 week-3.25%
Current month+15.25%
1 month+15.25%
3 months-1.04%
6 months-32.67%
Current year-52.06%
1 week 4.62
Extreme 4.62
5.13
1 month 3.99
Extreme 3.99
5.4
Current year 3.99
Extreme 3.99
10.75
1 year 3.99
Extreme 3.99
10.99
3 years 1.45
Extreme 1.45
22.33
5 years 1.45
Extreme 1.45
22.33
10 years 1.45
Extreme 1.45
22.33
Manager TitleAgeSince
Chief Executive Officer 46 31/12/2019
Director of Finance/CFO 50 14/08/2025
Chief Tech/Sci/R&D Officer 62 19/01/2026
Director TitleAgeSince
Director/Board Member 46 31/12/2019
Chairman 72 31/12/2020
Director/Board Member 61 31/10/2020
Date Insider Type Main position Quantity % Market Cap. Importance
18/08/26 Sell

Chief Executive Officer

-3,345 0.0043%
18/08/26 Sell

Chief Operating Officer

-1,304 0.0017%
18/08/26 Sell

Chief Financial Officer

-4,117 0.0052%
Change 5-day change 1-year change 3-year change Capi.($)
-2.06%-3.25%-0.63% - 391M
-1.66%-4.96%+49.84%+88.43% 68.13B
+0.69%+2.01%+45.53%+89.67% 63.6B
+1.31%+1.81%+37.52%+12.07% 25.57B
+2.77%-1.74%-16.16%+456.51% 26.6B
-0.46%-9.94%+0.98%-15.98% 25.52B
-9.71%-0.36%+245.87%+377.68% 18.23B
-0.33%-0.14%+28.56%-20.11% 19.69B
-1.49%-6.35%+0.78%+540.26% 15.16B
+0.35%+0.16%+46.96%+144.04% 13.54B
Average -1.06%-2.77%+43.93%+185.84% 27.64B
Weighted average by Cap. -0.64%-2.34%+45.35%+146.37%

Financials

2026 *2027 *
Net sales - -
Net income -104M -89.32M -83.87M -76.56M -144M -9.87B -145M -994M -387M -5.01B -389M -381M -16.57B -130M -112M -105M -95.96M -180M -12.37B -182M -1.25B -485M -6.27B -488M -478M -20.77B
Net Debt -178M -153M -144M -131M -246M -16.91B -248M -1.7B -662M -8.57B -667M -653M -28.39B -305M -263M -247M -225M -423M -29.05B -426M -2.92B -1.14B -14.73B -1.15B -1.12B -48.77B
Logo Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
Employees
63
Date Price Change Volume
31/08/26 US$4.760 -2.06% 472,037
28/08/26 US$4.860 -2.61% 663,606
27/08/26 US$4.990 -0.40% 1,105,720
26/08/26 US$5.010 -2.34% 689,958
25/08/26 US$5.130 +4.27% 937,384
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
4.760USD
Average target price
20.30USD
Spread / Average Target
+326.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LXEO Stock